114 results
Page 3 of 6
8-K
gt9qglnsjq
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
424B5
d4k3z2q1b
12 Aug 22
Prospectus supplement for primary offering
8:31am
8-K
xvek11
25 May 22
Regulation FD Disclosure
7:02am
8-K
EX-99.1
frkz9lst
25 May 22
Regulation FD Disclosure
7:02am
8-K
EX-1.1
lg8izuogdvn
13 Apr 22
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
4:26pm
424B5
m5j pyahc11y
13 Apr 22
Prospectus supplement for primary offering
4:22pm
8-K
EX-99.1
0hywhq t3r7i8
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
EX-99.2
w6mwcd7 earobdp
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
djwe0jvo
28 Feb 22
Entry into a Material Definitive Agreement
8:30am
424B5
gww382xae13
21 Oct 21
Prospectus supplement for primary offering
4:26pm
8-K
EX-1.1
l7nuv ev121mf
21 Oct 21
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:24pm
424B5
gaw 1f2nin
20 Oct 21
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
hdia liq2
15 Sep 21
Regulation FD Disclosure
4:05pm
S-3ASR
1cpload15td iu
10 Aug 21
Automatic shelf registration
5:25pm